| __timestamp | Halozyme Therapeutics, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79696000 | 22223073 |
| Thursday, January 1, 2015 | 93236000 | 6966842 |
| Friday, January 1, 2016 | 150842000 | 9000499 |
| Sunday, January 1, 2017 | 150643000 | 13741186 |
| Monday, January 1, 2018 | 150252000 | 19040000 |
| Tuesday, January 1, 2019 | 140804000 | 23559000 |
| Wednesday, January 1, 2020 | 34236000 | 31931000 |
| Friday, January 1, 2021 | 35672000 | 44981000 |
| Saturday, January 1, 2022 | 66607000 | 54234000 |
| Sunday, January 1, 2023 | 76363000 | 63806000 |
| Monday, January 1, 2024 | 79048000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Halozyme Therapeutics, Inc. and Viking Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Halozyme Therapeutics consistently allocated significant resources to R&D, peaking in 2016 with a 54% increase from the previous year. Despite a dip in 2020, their spending rebounded, reflecting a strategic focus on long-term growth and innovation.
Viking Therapeutics, on the other hand, showcased a remarkable upward trend, with R&D expenses growing nearly threefold from 2014 to 2023. This surge underscores their aggressive pursuit of new therapeutic solutions, positioning them as a rising star in the biotech sector.
Both companies exemplify the dynamic nature of biotech innovation, where strategic R&D investments pave the way for future breakthroughs.
GSK plc or Halozyme Therapeutics, Inc.: Who Invests More in Innovation?
Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Viking Therapeutics, Inc.
Analyzing R&D Budgets: Genmab A/S vs Viking Therapeutics, Inc.
R&D Insights: How Summit Therapeutics Inc. and Halozyme Therapeutics, Inc. Allocate Funds
Research and Development: Comparing Key Metrics for BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.
Research and Development Investment: Halozyme Therapeutics, Inc. vs PTC Therapeutics, Inc.
Research and Development Investment: Halozyme Therapeutics, Inc. vs Veracyte, Inc.
Halozyme Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Strategic Focus on R&D Spending
Blueprint Medicines Corporation vs Viking Therapeutics, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for TG Therapeutics, Inc. and Viking Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Viking Therapeutics, Inc. and Ligand Pharmaceuticals Incorporated
Analyzing R&D Budgets: Viking Therapeutics, Inc. vs Agios Pharmaceuticals, Inc.